BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27288464)

  • 1. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy.
    Cabanillas ME; Zafereo M; Gunn GB; Ferrarotto R
    J Oncol Pract; 2016 Jun; 12(6):511-8. PubMed ID: 27288464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
    Sasanakietkul T; Murtha TD; Javid M; Korah R; Carling T
    Mol Cell Endocrinol; 2018 Jul; 469():23-37. PubMed ID: 28552796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid Cancer: Risk-Stratified Management and Individualized Therapy.
    Raue F; Frank-Raue K
    Clin Cancer Res; 2016 Oct; 22(20):5012-5021. PubMed ID: 27742787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
    Abe I; Lam AK
    Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies.
    Molinaro E; Romei C; Biagini A; Sabini E; Agate L; Mazzeo S; Materazzi G; Sellari-Franceschini S; Ribechini A; Torregrossa L; Basolo F; Vitti P; Elisei R
    Nat Rev Endocrinol; 2017 Nov; 13(11):644-660. PubMed ID: 28707679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NGS based identification of mutational hotspots for targeted therapy in anaplastic thyroid carcinoma.
    Tiedje V; Ting S; Herold T; Synoracki S; Latteyer S; Moeller LC; Zwanziger D; Stuschke M; Fuehrer D; Schmid KW
    Oncotarget; 2017 Jun; 8(26):42613-42620. PubMed ID: 28489587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Perspectives Regarding Anaplastic Thyroid Carcinoma Approach Improvement.
    Figueiredo AS; Andrea-Ferreira P
    Endocr Metab Immune Disord Drug Targets; 2018; 18(6):555-564. PubMed ID: 29886838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive Palliation and Survival in Anaplastic Thyroid Carcinoma.
    Nachalon Y; Stern-Shavit S; Bachar G; Shvero J; Limon D; Popovtzer A
    JAMA Otolaryngol Head Neck Surg; 2015 Dec; 141(12):1128-32. PubMed ID: 26512447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy.
    Lennon P; Deady S; Healy ML; Toner M; Kinsella J; Timon CI; O'Neill JP
    Head Neck; 2016 Apr; 38 Suppl 1():E1122-9. PubMed ID: 26879282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Biomarkers of Anaplastic Thyroid Carcinoma.
    Bozorg-Ghalati F; Hedayati M
    Curr Mol Med; 2017; 17(3):181-188. PubMed ID: 28828971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic thyroid carcinoma: Updates on WHO classification, clinicopathological features and staging.
    Abe I; Lam AK
    Histol Histopathol; 2021 Mar; 36(3):239-248. PubMed ID: 33170501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of immune checkpoint inhibitors in anaplastic thyroid cancer (Case Series).
    Sukari A; Kukreja G; Nagasaka M; Shukairy MK; Yoo G; Lin HS; Hotaling J; Kim H
    Oral Oncol; 2020 Oct; 109():104744. PubMed ID: 32402656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spanish consensus for the management of patients with anaplastic cell thyroid carcinoma.
    Gómez Sáez JM; Jiménez-Fonseca P; Santamaría Sandi J; Capdevila Castillón J; Navarro González E; Zafón Llopis C; Ramón Y Cajal Asensio T; Riesco Eizaguirre G; Grande Pulido E; Galofré Ferrater JC
    Endocrinol Nutr; 2015 Mar; 62(3):e15-22. PubMed ID: 25583658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and Prognosis of Anaplastic Thyroid Carcinoma: A Clinical Study of 50 Cases.
    Liu TR; Xiao ZW; Xu HN; Long Z; Wei FQ; Zhuang SM; Sun XM; Xie LE; Mu JS; Yang AK; Zhang GP; Fan Y
    PLoS One; 2016; 11(10):e0164840. PubMed ID: 27760217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel therapeutic targets in anaplastic thyroid carcinoma using functional genomic mRNA-profiling: Paving the way for new avenues?
    Jonker PK; van Dam GM; Oosting SF; Kruijff S; Fehrmann RS
    Surgery; 2017 Jan; 161(1):202-211. PubMed ID: 27865593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision Medicine Approach to Anaplastic Thyroid Cancer: Advances in Targeted Drug Therapy Based on Specific Signaling Pathways.
    Samimi H; Fallah P; Naderi Sohi A; Tavakoli R; Naderi M; Soleimani M; Larijani B; Haghpanah V
    Acta Med Iran; 2017 Mar; 55(3):200-208. PubMed ID: 28282720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Re-understanding of the biological behavior of anaplastic thyroid carcinoma].
    Zhou YK; Shi BY
    Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(5):375-377. PubMed ID: 36740397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic Thyroid Cancer: New Horizons and Challenges.
    Maniakas A; Zafereo M; Cabanillas ME
    Endocrinol Metab Clin North Am; 2022 Jun; 51(2):391-401. PubMed ID: 35662448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic thyroid cancer.
    Ranganath R; Shah MA; Shah AR
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):387-91. PubMed ID: 26313900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.